NASDAQ
Aperture Investors LLC lifted its holdings in shares of Vertex, Inc. (NASDAQ: VERX) by 11.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Ex...
California-based Tensile Capital Management increased its position in Vertex by 160,559 shares in the third quarter. Despite the increase in shares, the position value fell by about $34.4 million from...
Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years a...
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peo...
KING OF PRUSSIA, Pa., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, and CPA.com, the trusted partner in ...
Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion....
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum....
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eighteen analysts that are currently covering the company, Marketbeat.com reports. One e...
Bank of New York Mellon Corp lifted its stake in shares of Vertex, Inc. (NASDAQ: VERX) by 14.7% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The i...
No price data available for this timeframe.